131 related articles for article (PubMed ID: 15958840)
1. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.
Zaccarelli M; Tozzi V; Lorenzini P; Trotta MP; Forbici F; Visco-Comandini U; Gori C; Narciso P; Perno CF; Antinori A;
AIDS; 2005 Jul; 19(10):1081-9. PubMed ID: 15958840
[TBL] [Abstract][Full Text] [Related]
2. The V118I mutation as a marker of advanced HIV infection and disease progression.
Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
[TBL] [Abstract][Full Text] [Related]
3. Continuous evidence of fast HIV disease progression related to class-wide resistance to antiretroviral drugs: a 6 year follow-up analysis of a large observational database.
Mauro Z; Federica F; Patrizia L; Francesca CS; Valerio T; Paola TM; Patrizia M; Pasquale N; Federico PC; Andrea A
AIDS; 2007 Aug; 21(13):1824-6. PubMed ID: 17690586
[TBL] [Abstract][Full Text] [Related]
4. Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.
Zaccarelli M; Lorenzini P; Tozzi V; Forbici F; Ceccherini-Silberstein F; Gori C; D'Arrigo R; Trotta MP; Narciso P; Perno CF; Antinori A;
Infection; 2009 Jun; 37(3):203-9. PubMed ID: 19274429
[TBL] [Abstract][Full Text] [Related]
5. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
[TBL] [Abstract][Full Text] [Related]
6. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
[TBL] [Abstract][Full Text] [Related]
7. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
[TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
9. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy.
Ormaasen V; Sandvik L; Asjø B; Holberg-Petersen M; Gaarder PI; Bruun JN
HIV Med; 2004 Nov; 5(6):400-6. PubMed ID: 15544691
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
[TBL] [Abstract][Full Text] [Related]
11. Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trial.
De Luca A; Di Giambenedetto S; Cingolani A; Bacarelli A; Ammassari A; Cauda R
Antivir Ther; 2006; 11(3):321-7. PubMed ID: 16759048
[TBL] [Abstract][Full Text] [Related]
12. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.
Ghosn J; Wirden M; Ktorza N; Peytavin G; Aït-Mohand H; Schneider L; Dominguez S; Bricaire F; Calvez V; Costagliola D; Katlama C
AIDS; 2005 Oct; 19(15):1643-7. PubMed ID: 16184034
[TBL] [Abstract][Full Text] [Related]
13. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
[TBL] [Abstract][Full Text] [Related]
14. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing.
Lucas GM; Gallant JE; Moore RD
AIDS; 2004 Jul; 18(11):1539-48. PubMed ID: 15238772
[TBL] [Abstract][Full Text] [Related]
15. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
Di Giambenedetto S; Bracciale L; Colafigli M; Cattani P; Pinnetti C; Bacarelli A; Prosperi M; Fadda G; Cauda R; De Luca A
Antivir Ther; 2007; 12(5):835-9. PubMed ID: 17713168
[TBL] [Abstract][Full Text] [Related]
16. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
17. Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.
Badri SM; Adeyemi OM; Max BE; Hota BN; Barker DE
AIDS Patient Care STDS; 2007 Aug; 21(8):544-50. PubMed ID: 17711379
[TBL] [Abstract][Full Text] [Related]
18. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
19. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
Cozzi-Lepri A; Phillips AN; Ruiz L; Clotet B; Loveday C; Kjaer J; Mens H; Clumeck N; Viksna L; Antunes F; Machala L; Lundgren JD;
AIDS; 2007 Mar; 21(6):721-32. PubMed ID: 17413693
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
